Niclosamide, a potent antineoplastic drug that inactivates the NF-κB pathway and increases the ROS level, can preferentially kill progenitor/stem cells from acute myelogenous leukemia (AML) patients but spare those from normal bone marrow [175]. Here, NFKB1 is linked to acute myeloid leukemia.